Suven Life Sciences gets product patents for CNS molecule

Suven Life Sciences has received one product patent each from New Zealand, Singapore and the US for its new molecule which seeks to target neuro-degenerative diseases of the central nervous system.
"The patents are valid through 2032," Suven Life Sciences said in a filing to the BSE.
With the grant of the new patents, Suven has a total of 24 patent approvals from New Zealand, 22 from Singapore and 22 from the US, it added.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally", said CEO Venkat Jasti.

Products out of these inventions may be out-licenced at various phases of clinical development like at Phase-I or Phase-II, Suven said.
The molecules are being developed for the treatment of cognitive impairment associated with neuro-degenerative disorders such as Alzheimer's disease, attention deficient hyperactivity disorder, Huntington's disease, Parkinson and schizophrenia.
Suven Life Sciences shares closed 7.11% per cent up at Rs 286.25 per scrip on the BSE.